ArticleCancer biology & therapy2017

Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.

Afia Muhammad Akram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.